100 assets in Marginal Zone Lymphoma

Therapeutic assets addressing Marginal Zone Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Etoposide Marginal Zone Lymphoma	University of Miami	P2	BBB (75)
Orelabrutinib Marginal Zone Lymphoma	Henan Cancer Hospital	P4	BBB (73)
Cyclosporin A Marginal Zone Lymphoma	Fred Hutchinson Cancer Center	P2	BBB (72)
Nivestim Marginal Zone Lymphoma	Fred Hutchinson Cancer Center	P2	BBB (72)
Vincristine Sulfate Marginal Zone Lymphoma	Mayo Clinic	P2	BBB (72)
Fludarabine Marginal Zone Lymphoma	Paolo Caimi, MD	P2	BB (70)
Rituximab Marginal Zone Lymphoma	City of Hope Medical Center	P4	BB (70)
Busulfanum Marginal Zone Lymphoma	Masonic Cancer Center, University of Minnesota	P2	BB (69)
Tacrolimus Marginal Zone Lymphoma	Masonic Cancer Center, University of Minnesota	P2	BB (69)
Dexasone Marginal Zone Lymphoma	Izidore Lossos, MD	P3	BB (68)
Lenalidomide Marginal Zone Lymphoma	Henan Cancer Hospital	P3	BB (68)
Pegfilgrastim Marginal Zone Lymphoma	Mayo Clinic	P2	BB (67)
Zanubrutinib Marginal Zone Lymphoma	Zhengzhou University	P3	BB (67)
Adriamycin Marginal Zone Lymphoma	Henan Cancer Hospital	P3	BB (65)
Nivolumab Marginal Zone Lymphoma	University of Washington	P2	BB (65)
Pirtobrutinib Marginal Zone Lymphoma	University of Utah	P2	BB (65)
Prednisone Marginal Zone Lymphoma	Henan Cancer Hospital	P3	BB (65)
Bendamustine Marginal Zone Lymphoma	Henan Cancer Hospital	P3	BB (64)
Obinutuzumab Marginal Zone Lymphoma	Ruijin Hospital	P3	BB (64)
Venetoclax Marginal Zone Lymphoma	Gottfried von Keudell, MD PhD	P2	BB (64)
(+)-Vincristine Marginal Zone Lymphoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P3	BB (64)
Cyclophosphamide Marginal Zone Lymphoma	Paolo Caimi, MD	P3	B (63)
Epirubicin Marginal Zone Lymphoma	University of Ulm	P2	B (63)
Ibrutinib Marginal Zone Lymphoma	Academic and Community Cancer Research United	P3	B (63)
Pembrolizumab Marginal Zone Lymphoma	University of Ulm	P2	B (63)
Acalabrutinib Marginal Zone Lymphoma	Narendranath Epperla	P2	B (62)
Polatuzumab Vedotin Marginal Zone Lymphoma	University of Washington	P2	B (62)
Sirolimus Marginal Zone Lymphoma	Masonic Cancer Center, University of Minnesota	P2	B (61)
Parsaclisib Marginal Zone Lymphoma	Incyte Corporation	P3	B (60)
Recombinant Human Hyaluronidase Marginal Zone Lymphoma	Academic and Community Cancer Research United	P2	B (60)
Mosunetuzumab Marginal Zone Lymphoma	University of Washington	P3	B (59)
Oxaliplatin Marginal Zone Lymphoma	Izidore Lossos, MD	P2	B (58)
Tafasitamab Marginal Zone Lymphoma	Paolo Caimi, MD	P3	B (58)
Ublituximab Marginal Zone Lymphoma	Yazeed Sawalha	P2/3	B (57)
Azacitidine Marginal Zone Lymphoma	Prelude Therapeutics	P2	CCC (55)
Epcoritamab Marginal Zone Lymphoma	Izidore Lossos, MD	P2	CCC (55)
Loncastuximab Tesirine Marginal Zone Lymphoma	University of Miami	P2	CCC (55)
Nemtabrutinib Marginal Zone Lymphoma	City of Hope Medical Center	P2	CCC (55)
Boclatixafortide Marginal Zone Lymphoma	Pentixapharm AG	P3	CCC (54)
Duvelisib Marginal Zone Lymphoma	Ruijin Hospital	P3	CCC (54)
Fludeoxyglucose Marginal Zone Lymphoma	Pentixapharm AG	P3	CCC (54)
Thiotepa Marginal Zone Lymphoma	Fred Hutchinson Cancer Center	P2	CCC (54)
Lisaftoclax Marginal Zone Lymphoma	Henan Cancer Hospital	P2	CCC (53)
Treosulfan Marginal Zone Lymphoma	Fred Hutchinson Cancer Center	P2	CCC (53)
Zebetuzumab Marginal Zone Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P2	CCC (53)
Zuberitamab Marginal Zone Lymphoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Umbralisib Marginal Zone Lymphoma	Yazeed Sawalha	P2/3	CCC (52)
Allopurinol Marginal Zone Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Copanlisib Marginal Zone Lymphoma	Christian Buske	P2	CCC (51)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine) Marginal Zone Lymphoma	Reid Merryman, MD	P2	CCC (51)

Showing 1 to 50 of 100 assets

PreviousPage 1 of 2Next